The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia

MUC16 (the cancer antigen CA125) is the most commonly used serum biomarker in epithelial ovarian cancer, with increasing levels reflecting disease progression. It is a transmembrane glycoprotein with multiple isoforms, undergoing significant changes through the metastatic process. Aberrant glycosyla...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Carcinogenesis (New York) Jg. 42; H. 3; S. 327
Hauptverfasser: Giamougiannis, Panagiotis, Martin-Hirsch, Pierre L, Martin, Francis L
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England 17.04.2021
ISSN:1460-2180, 1460-2180
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract MUC16 (the cancer antigen CA125) is the most commonly used serum biomarker in epithelial ovarian cancer, with increasing levels reflecting disease progression. It is a transmembrane glycoprotein with multiple isoforms, undergoing significant changes through the metastatic process. Aberrant glycosylation and cleavage with overexpression of a small membrane-bound fragment consist MUC16-related mechanisms that enhance malignant potential. Even MUC16 knockdown can induce an aggressive phenotype but can also increase susceptibility to chemotherapy. Variable MUC16 functions help ovarian cancer cells avoid immune cytotoxicity, survive inside ascites and form metastases. This review provides a comprehensive insight into MUC16 transformations and interactions, with description of activated oncogenic signalling pathways, and adds new elements on the role of its differential glycosylation. By following the journey of the molecule from pre-malignant states to advanced stages of disease it demonstrates its behaviour, in relation to the phenotypic shifts and progression of ovarian cancer. Additionally, it presents proposed differences of MUC16 structure in normal/benign conditions and epithelial ovarian malignancy.
AbstractList MUC16 (the cancer antigen CA125) is the most commonly used serum biomarker in epithelial ovarian cancer, with increasing levels reflecting disease progression. It is a transmembrane glycoprotein with multiple isoforms, undergoing significant changes through the metastatic process. Aberrant glycosylation and cleavage with overexpression of a small membrane-bound fragment consist MUC16-related mechanisms that enhance malignant potential. Even MUC16 knockdown can induce an aggressive phenotype but can also increase susceptibility to chemotherapy. Variable MUC16 functions help ovarian cancer cells avoid immune cytotoxicity, survive inside ascites and form metastases. This review provides a comprehensive insight into MUC16 transformations and interactions, with description of activated oncogenic signalling pathways, and adds new elements on the role of its differential glycosylation. By following the journey of the molecule from pre-malignant states to advanced stages of disease it demonstrates its behaviour, in relation to the phenotypic shifts and progression of ovarian cancer. Additionally, it presents proposed differences of MUC16 structure in normal/benign conditions and epithelial ovarian malignancy.MUC16 (the cancer antigen CA125) is the most commonly used serum biomarker in epithelial ovarian cancer, with increasing levels reflecting disease progression. It is a transmembrane glycoprotein with multiple isoforms, undergoing significant changes through the metastatic process. Aberrant glycosylation and cleavage with overexpression of a small membrane-bound fragment consist MUC16-related mechanisms that enhance malignant potential. Even MUC16 knockdown can induce an aggressive phenotype but can also increase susceptibility to chemotherapy. Variable MUC16 functions help ovarian cancer cells avoid immune cytotoxicity, survive inside ascites and form metastases. This review provides a comprehensive insight into MUC16 transformations and interactions, with description of activated oncogenic signalling pathways, and adds new elements on the role of its differential glycosylation. By following the journey of the molecule from pre-malignant states to advanced stages of disease it demonstrates its behaviour, in relation to the phenotypic shifts and progression of ovarian cancer. Additionally, it presents proposed differences of MUC16 structure in normal/benign conditions and epithelial ovarian malignancy.
MUC16 (the cancer antigen CA125) is the most commonly used serum biomarker in epithelial ovarian cancer, with increasing levels reflecting disease progression. It is a transmembrane glycoprotein with multiple isoforms, undergoing significant changes through the metastatic process. Aberrant glycosylation and cleavage with overexpression of a small membrane-bound fragment consist MUC16-related mechanisms that enhance malignant potential. Even MUC16 knockdown can induce an aggressive phenotype but can also increase susceptibility to chemotherapy. Variable MUC16 functions help ovarian cancer cells avoid immune cytotoxicity, survive inside ascites and form metastases. This review provides a comprehensive insight into MUC16 transformations and interactions, with description of activated oncogenic signalling pathways, and adds new elements on the role of its differential glycosylation. By following the journey of the molecule from pre-malignant states to advanced stages of disease it demonstrates its behaviour, in relation to the phenotypic shifts and progression of ovarian cancer. Additionally, it presents proposed differences of MUC16 structure in normal/benign conditions and epithelial ovarian malignancy.
Author Giamougiannis, Panagiotis
Martin, Francis L
Martin-Hirsch, Pierre L
Author_xml – sequence: 1
  givenname: Panagiotis
  surname: Giamougiannis
  fullname: Giamougiannis, Panagiotis
  organization: School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, UK
– sequence: 2
  givenname: Pierre L
  surname: Martin-Hirsch
  fullname: Martin-Hirsch, Pierre L
  organization: Division of Cancer Sciences, University of Manchester, Manchester, UK
– sequence: 3
  givenname: Francis L
  surname: Martin
  fullname: Martin, Francis L
  organization: Biocel UK Ltd, Hull, UK
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33608706$$D View this record in MEDLINE/PubMed
BookMark eNpN0DtPwzAQwHELFdEHrIzIYxlC_Yprj1XESypiaefonDrFVWIXO63EtyeFIrH4bvjp9JfHaOCDtwjdUvJAieazCmLl_MxswRBKLtCICkkyRhUZ_NuHaJzSjhAqea6v0JBzSdScyBHarT4stsfQHJ3f4hgai0ON39YFlXhaLCjL77HzuOtVF8GnOsQWOhf8iYUjRAceV7ZpEga_-XH7GLbRpnRG3oZ9A8nBNbqsoUn25jwnaP30uCpesuX782uxWGaV4HmX1ZSB0YaABKs3uhaCqrlVNRCtLOiqT6p4bg0zjNdKgVRa9q9UhCuSU80maPp7tw_5PNjUla1Lp0ToUw6pZEJTLYTQsqd3Z3owrd2U--haiF_l3_-wb8gLaRc
CitedBy_id crossref_primary_10_1186_s12967_024_05351_z
crossref_primary_10_1016_j_aca_2024_342765
crossref_primary_10_3390_biom15091260
crossref_primary_10_1007_s00216_021_03472_8
crossref_primary_10_1016_j_critrevonc_2023_104237
crossref_primary_10_1093_carcin_bgac084
crossref_primary_10_1016_j_arabjc_2023_105070
crossref_primary_10_3390_pharmaceutics13101705
crossref_primary_10_1097_MD_0000000000034839
crossref_primary_10_1007_s00604_024_06740_3
crossref_primary_10_1111_jcmm_70633
crossref_primary_10_1016_j_microc_2023_109276
crossref_primary_10_1186_s12885_023_10588_w
crossref_primary_10_1186_s12885_023_10791_9
crossref_primary_10_3390_biom15040602
crossref_primary_10_1016_j_cca_2024_119981
crossref_primary_10_1186_s13048_022_01066_1
crossref_primary_10_1007_s10238_024_01365_5
crossref_primary_10_34172_apb_2024_028
crossref_primary_10_3390_diagnostics12122985
crossref_primary_10_3390_cancers15030667
crossref_primary_10_1155_2022_6734105
crossref_primary_10_1093_glycob_cwad035
crossref_primary_10_1038_s41598_024_84622_7
crossref_primary_10_1016_j_tjog_2023_09_017
crossref_primary_10_3390_diagnostics12123177
crossref_primary_10_1186_s12885_025_13461_0
crossref_primary_10_3390_nu15112611
crossref_primary_10_1002_cam4_7228
crossref_primary_10_1038_s41698_023_00423_7
crossref_primary_10_1007_s10719_021_10027_7
crossref_primary_10_3389_fonc_2021_732447
crossref_primary_10_1093_carcin_bgab127
crossref_primary_10_3390_cancers14153580
crossref_primary_10_1002_jbio_202100195
crossref_primary_10_3390_ijms22126502
ContentType Journal Article
Copyright The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Copyright_xml – notice: The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
DBID NPM
7X8
DOI 10.1093/carcin/bgab010
DatabaseName PubMed
MEDLINE - Academic
DatabaseTitle PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1460-2180
ExternalDocumentID 33608706
Genre Journal Article
GroupedDBID ---
-E4
.2P
.I3
.ZR
0R~
18M
1TH
29B
2WC
4.4
482
48X
5GY
5RE
5VS
5WA
5WD
6J9
70D
A8Z
AABZA
AACZT
AAIMJ
AAJKP
AAMDB
AAMVS
AAOGV
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAVAP
AAVLN
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABLJU
ABMNT
ABNHQ
ABNKS
ABPTD
ABQLI
ABVGC
ABWST
ABXVV
ABZBJ
ACGFO
ACGFS
ACNCT
ACPRK
ACUFI
ACUTJ
ACUTO
ADBBV
ADEYI
ADEZT
ADFTL
ADGKP
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADVEK
ADYVW
ADZTZ
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AELWJ
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFZL
AFGWE
AFIYH
AFOFC
AFRAH
AFXEN
AGINJ
AGKEF
AGQXC
AGSYK
AHMBA
AHMMS
AHXPO
AIAGR
AIJHB
AJEEA
AKHUL
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
APIBT
APWMN
ARIXL
ATGXG
AXUDD
AYOIW
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BQDIO
BSWAC
BTRTY
BVRKM
C45
CDBKE
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBD
EBS
EE~
EMOBN
F5P
F9B
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
FRP
GAUVT
GJXCC
GX1
H13
H5~
HAR
HW0
HZ~
IH2
IOX
J21
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
M-Z
M49
N9A
NGC
NLBLG
NOMLY
NOYVH
NPM
NU-
O9-
OAWHX
OBOKY
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
RHF
ROL
ROX
RUSNO
RW1
RXO
SV3
TEORI
TJX
TLC
TR2
W8F
WOQ
X7H
YAYTL
YKOAZ
YXANX
ZKX
~91
7X8
ABPQP
ABXZS
ADNBA
AFYAG
AHGBF
AJBYB
AJNCP
ALXQX
ESTFP
JXSIZ
ID FETCH-LOGICAL-c435t-f12ab9b0a6ae9d9f44187e8fa098ea9c125c35eb2b23f88a68968a66803805192
IEDL.DBID 7X8
ISICitedReferencesCount 44
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000648928600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1460-2180
IngestDate Thu Oct 02 09:05:58 EDT 2025
Wed Feb 19 02:28:55 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
License The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c435t-f12ab9b0a6ae9d9f44187e8fa098ea9c125c35eb2b23f88a68968a66803805192
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink https://academic.oup.com/carcin/article-pdf/42/3/327/37119068/bgab010.pdf
PMID 33608706
PQID 2491944496
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2491944496
pubmed_primary_33608706
PublicationCentury 2000
PublicationDate 2021-Apr-17
PublicationDateYYYYMMDD 2021-04-17
PublicationDate_xml – month: 04
  year: 2021
  text: 2021-Apr-17
  day: 17
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Carcinogenesis (New York)
PublicationTitleAlternate Carcinogenesis
PublicationYear 2021
SSID ssj0016359
Score 2.5335546
SecondaryResourceType review_article
Snippet MUC16 (the cancer antigen CA125) is the most commonly used serum biomarker in epithelial ovarian cancer, with increasing levels reflecting disease progression....
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 327
Title The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia
URI https://www.ncbi.nlm.nih.gov/pubmed/33608706
https://www.proquest.com/docview/2491944496
Volume 42
WOSCitedRecordID wos000648928600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5qRbz4fj-I4EEPS7PJNpucRIrFS0sPFnorSTaReshWW_39zuyu1osgeMlpFobsl8w3j8wQcu1ch7OgRZJnEh2UEKoxLwnLuZXWFwXnoRo2kQ8GajzWwybgNm_KKr_uxOqiLkqHMfI2uAngb2eZlnez1wSnRmF2tRmhsUpaAqgMojofL7MIYEx1_bqIJWDK2HfTRtF2OKkntu2zsSxlv9PLysz0tv-r4A7Zaggmva8RsUtWfNwjG_0mhb5PXgAY1MOlhJEEisWFtAy0P-qmkt5074GJ3NJppMAL6eIHqS0jipUf4FqbSDHcP6cmFpVcVeNV9_dAoYhF6fg484CMeg9P3cekGbiQOGBNiySk3FhtmZHG60IHoEoq9yoYppU32oEKTnTAF7dcBKWMVFrCKhUTCqkgPyRrsYz-mFBtndBFqnXh88wATIB5mBT8bQvmMOP2hFx97eIEAI1qG1DvfT5Z7uMJOap_xWRWd96YCCEZJmZP__D1GdnkWH-CfRnzc9IKcJz9BVl3H4vp_O2yQgqsg2H_E1ylyGE
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+evolving+role+of+MUC16+%28CA125%29+in+the+transformation+of+ovarian+cells+and+the+progression+of+neoplasia&rft.jtitle=Carcinogenesis+%28New+York%29&rft.au=Giamougiannis%2C+Panagiotis&rft.au=Martin-Hirsch%2C+Pierre+L&rft.au=Martin%2C+Francis+L&rft.date=2021-04-17&rft.issn=1460-2180&rft.eissn=1460-2180&rft.volume=42&rft.issue=3&rft.spage=327&rft_id=info:doi/10.1093%2Fcarcin%2Fbgab010&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1460-2180&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1460-2180&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1460-2180&client=summon